Drugs News and Research

RSS

New UM SOM study reveals why thiazide drugs not effective in some patients

Every year, more than 120 million prescriptions are written worldwide for thiazide drugs, a group of salt-lowering medicines used to treat high blood pressure. These drugs are often work very well, and over decades have saved hundreds of thousands of lives.

21 Apr 2015

CML guidelines highlight need for TKI switch timing, choice

A review of the European LeukemiaNet guidelines on the care of patients with chronic myeloid leukaemia highlights the need for research into the timing and use of second-line and third-line tyrosine kinase inhibitors.

20 Apr 2015

Two existing drugs may potentially become new drug target for multiple sclerosis

Two drugs already on the market -- an antifungal and a steroid -- may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis.

20 Apr 2015

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse).

20 Apr 2015

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune diseases, today announced clinical trial data from the Phase I/IIa study of its lead programme IMCgp100, at the American Association for Cancer Research Annual Meeting 2015, in Philadelphia, USA.

20 Apr 2015

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

20 Apr 2015

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.

20 Apr 2015

Countering Ebola misinformation: an interview with Dr Katie Geary, International SOS

People tried to avoid a healthcare situation and in doing so, they propagated it through the community because instead of being in isolation they remained around the family group and relied on usual cultural health remedies...

20 Apr 2015

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

20 Apr 2015

Scientists reveal three major subsets of KRAS-mutant LUAC

Mutations of the KRAS gene are commonly known to lead to cancer. However, deeper understanding of exactly how they do this continues to be explored by cancer researchers.

20 Apr 2015

Research explores new, personalized ovarian cancer treatments

Identifying molecular changes that occur in tissue after chemotherapy could be crucial in advancing treatments for ovarian cancer, according to research from Magee-Womens Research Institute and Foundation and the University of Pittsburgh Cancer Institute, partner with UPMC CancerCenter, presented today at the American Association for Cancer Research Annual Meeting 2015.

20 Apr 2015

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

20 Apr 2015

Paradigm to provide PCDx test to oncologists in TD2 networks

Paradigm and Translational Drug Development today announced a partnership under which Paradigm will provide their PCDx test to TD2's affiliated oncology provider networks.

20 Apr 2015

RetroSense Therapeutics receives Luis Villalobos Award

RetroSense Therapeutics, LLC, a Wayne State University start-up biotechnology company, has received the Luis Villalobos Award from the Angel Capital Association, the world's leading professional association for angel investors.

20 Apr 2015

Malaria parasites with Ap2mu gene mutation less sensitive to antimalarial drug artemisinin

Early indicators of the malaria parasite in Africa developing resistance to the most effective drug available have been confirmed, according to new research published in Antimicrobial Agents and Chemotherapy.

20 Apr 2015

Some lung cancer patients can benefit from melanoma drugs

A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.

20 Apr 2015

Study sheds light on the physical causes of sudden death

Sudden cardiac death accounts for approximately 10% of natural deaths, most of which are due to ventricular fibrillation. Each year it causes 300,000 deaths in the United States and 20,000 in Spain.

17 Apr 2015

Researchers explore benefits and risks of biosimilar antibodies

In the emerging biosimilar market, biosimilar antibodies are being developed to treat conditions currently addressed by their original, targeted biological therapy. Only a few biosimilars are approved by the EMA, and just one has been approved by the FDA. In a review article, researchers used the clinical development data from one drug to explore the broader benefits and risks of these cost-effective, but as yet unfamiliar treatment options.

17 Apr 2015

Inflammation plays causal role in neurologic changes associated with Lyme disease

About 15% of patients with Lyme disease develop peripheral and central nervous system involvement, often accompanied by debilitating and painful symptoms. New research indicates that inflammation plays a causal role in the array of neurologic changes associated with Lyme disease, according to a study published in The American Journal of Pathology.

17 Apr 2015

James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

The 2015 Pezcoller Foundation-American Association for Cancer Research (AACR) International Award for Cancer Research will be presented to James P. Allison, PhD, at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

17 Apr 2015

Drugs News and Research

New UM SOM study reveals why thiazide drugs not effective in some patients

CML guidelines highlight need for TKI switch timing, choice

Two existing drugs may potentially become new drug target for multiple sclerosis

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Countering Ebola misinformation: an interview with Dr Katie Geary, International SOS

New drug combination shows promise in patients with metastatic melanoma

Scientists reveal three major subsets of KRAS-mutant LUAC

Research explores new, personalized ovarian cancer treatments

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

Paradigm to provide PCDx test to oncologists in TD2 networks

RetroSense Therapeutics receives Luis Villalobos Award

Malaria parasites with Ap2mu gene mutation less sensitive to antimalarial drug artemisinin

Some lung cancer patients can benefit from melanoma drugs

Study sheds light on the physical causes of sudden death

Researchers explore benefits and risks of biosimilar antibodies

Inflammation plays causal role in neurologic changes associated with Lyme disease

James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News